Literature DB >> 20623787

Questions regarding frontline therapy of acute myeloid leukemia.

Hagop Kantarjian, Susan O'Brien.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20623787     DOI： 10.1002/cncr.25281

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  12 in total

Review 1.  Novel drugs for older patients with acute myeloid leukemia.

Authors:  G Montalban-Bravo; G Garcia-Manero
Journal:  Leukemia       Date:  2014-08-21       Impact factor: 11.528

2.  Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study.

Authors:  Enrique M Ocio; Pilar Herrera; María-Teresa Olave; Nerea Castro; José A Pérez-Simón; Salut Brunet; Albert Oriol; Marta Mateo; Miguel-Ángel Sanz; Javier López; Pau Montesinos; María-Carmen Chillón; María-Isabel Prieto-Conde; María Díez-Campelo; Marcos González; María-Belén Vidriales; María-Victoria Mateos; Jesús F San Miguel
Journal:  Haematologica       Date:  2015-07-09       Impact factor: 9.941

3.  Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.

Authors:  Daniel A Pollyea; James Zehnder; Steve Coutre; Jason R Gotlib; Leonel Gallegos; Omar Abdel-Wahab; Peter Greenberg; Bing Zhang; Michaela Liedtke; Caroline Berube; Ross Levine; Beverly S Mitchell; Bruno C Medeiros
Journal:  Haematologica       Date:  2012-12-14       Impact factor: 9.941

4.  Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study.

Authors:  Hagop Kantarjian; Stefan Faderl; Guillermo Garcia-Manero; Selina Luger; Parameswaran Venugopal; Lori Maness; Meir Wetzler; Steven Coutre; Wendy Stock; David Claxton; Stuart L Goldberg; Martha Arellano; Stephen A Strickland; Karen Seiter; Gary Schiller; Elias Jabbour; Judy Chiao; William Plunkett
Journal:  Lancet Oncol       Date:  2012-10-15       Impact factor: 41.316

5.  A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia.

Authors:  Sonia Christian; Saad Arain; Pritesh Patel; Irum Khan; Gregory S Calip; Vaibhav Agrawal; Karen Sweiss; Shawn Griffin; Kirk Cahill; Heiko Konig; Aysenur Esen; Ardaman Shergill; Olatoyosi Odenike; Wendy Stock; John G Quigley
Journal:  Am J Hematol       Date:  2020-05-08       Impact factor: 13.265

Review 6.  Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy.

Authors:  B T Gjertsen; P Schöffski
Journal:  Leukemia       Date:  2014-07-16       Impact factor: 11.528

7.  Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia.

Authors:  Yukio Kobayashi; Takahiro Yamauchi; Hitoshi Kiyoi; Toru Sakura; Tomoko Hata; Kiyoshi Ando; Aiko Watabe; Akiko Harada; Tillmann Taube; Yasushi Miyazaki; Tomoki Naoe
Journal:  Cancer Sci       Date:  2015-10-21       Impact factor: 6.716

8.  The eukaryotic translation initiation factor eIF4E wears a "cap" for many occasions.

Authors:  Katherine L B Borden
Journal:  Translation (Austin)       Date:  2016-08-10

Review 9.  Acute Myeloid Leukemia in the Elderly Patient: New Strategies.

Authors:  Xavier Thomas
Journal:  Rare Cancers Ther       Date:  2015-07-04

Review 10.  Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia.

Authors:  Mingxue Fan; Minghao Li; Lipeng Gao; Sicong Geng; Jing Wang; Yiting Wang; Zhiqiang Yan; Lei Yu
Journal:  J Hematol Oncol       Date:  2017-08-29       Impact factor: 17.388
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.